Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel

• US 10,532,045 B2
• Filed: 12/18/2014
• Issued: 01/14/2020
• Est. Priority Date: 12/18/2013
• Status: Active Grant

• Current Assignee: SignPath Pharma, Inc.
• Original Assignee: SignPath Pharma, Inc.
• Inventors: Helson, Lawrence, Shopp, George M., Bouchard, Annie
• Primary Examiner(s): Roney, Celeste A
• Application Number:
  US14/575,644
• Publication Number:
  US 20150164878A1
• Time in Patent Office: 1,853 Days
• Field of Search: None
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of I_Kr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.

Claims

1. A composition for treating or preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject consisting of:

one or more pharmacologically active agents provided in an amount that inhibits the activity of an ether-a-go-go-related gene (hERG), wherein the one or more pharmacologically active agents are kinase inhibitors selected from crizotinib and nilotinib, wherein the amount of the one or more pharmacologically active agents is sufficient to treat a cancer, wherein the cancer is selected from non-small cell lung cancer or chronic myeloid leukemia;

one or more empty liposomes, wherein the empty liposomes are administered prior to, concomitantly, or after administration of the pharmacologically active agent, wherein the one or more empty liposomes are provided in an amount effective to reduce the cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, and the empty liposomes consist of at least one liposome selected from at least one of phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, cerebrosides, dicetylphosphate, dipalmitoyl-phosphatidylglycerol, stearylamine, dodecylamine, hexadecyl-amine, acetyl palmitate, glycerol ricinoleate, hexadecyl sterate, isopropyl myristate, amphoteric acrylic polymers, fatty acid, fatty acid amides, diacylglycerol, diacylglycerolsuccinate, DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), or DMPG (1,2-dimyristoyl-sn-glycero-3-phospho-rac-[1-glycerol]).

2. The composition of claim 1, wherein the composition is used for the treatment or prevention of non-cardiac diseases of hERG.

3. The composition of claim 1, wherein the composition is adapted for enteral, parenteral, intravenous, intraperitoneal, or oral administration.

4. The composition of claim 1, wherein the active agent and the one or more empty liposomes may be bound or conjugated together.

5. The composition of claim 1, wherein the one or more empty liposomes consist essentially of anionic, cationic, or neutral lipids.

6. The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable dispersion medium, solvent, or vehicle, wherein the active agent, the one or more empty liposomes or both are dissolved, dispersed, or suspended in the medium, the solvent, or the vehicle.

7. A composition for preventing or treating one or more adverse reactions arising from administration of a therapeutically active agent or a drug in a human that inhibits the activity of an ether-a-go-go-related gene (hERG) consisting of:

one or more pharmacologically active agents provided in an amount that causes at least one of IKr channel inhibition or QT prolongation and one or more empty liposomes, wherein the one or more pharmacologically active agents are kinase inhibitors selected from crizotinib and nilotinib, wherein the amount of the one or more pharmacologically active agents is sufficient to treat a cancer, wherein the cancer is selected from non-small cell lung cancer or chronic myeloid leukemia; and

one or more empty liposomes are administered prior to, concomitantly, or after administration of the therapeutically active agent or the drug in an amount effective to reduce the adverse reactions arising from administration of the therapeutically active agent or drug, and the one or more empty liposomes consist essentially of one or more lipids selected from phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, cerebrosides, dicetylphosphate, dipalmitoyl-phosphatidylglycerol, stearylamine, dodecylamine, hexadecyl-amine, acetyl palmitate, glycerol ricinoleate, hexadecyl sterate, isopropyl myristate, amphoteric acrylic polymers, fatty acid, fatty acid amides, diacylglycerol, diacylglycerolsuccinate, DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), or DMPG (1,2-dimyristoyl-sn-glycero-3-phospho-rac-[1-glycerol]).

8. The composition of claim 7, wherein the therapeutically active agent or a drug is used in a prevention or a treatment of one or more cardiac or non-cardiac diseases in the human or animal subject.

9. The composition of claim 7, wherein the composition is used for the treatment or prevention of non-cardiac related diseases of hERG.

10. The composition of claim 7, wherein the composition is adapted for enteral, parenteral, intravenous, intraperitoneal, or oral administration.

11. The composition of claim 7, wherein the active agent and the one or more empty liposomes may be bound or conjugated together.

12. The composition of claim 7, wherein the one or more empty liposomes consist essentially of anionic, cationic, or neutral lipids.

13. The composition of claim 7, wherein the one or more empty liposomes comprise DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) and DMPG (1,2-dimyristoyl-sn-glycero-3-phospho-rac-[1-glycerol]).